Anna Gumieniczek

Prof. Anna Gumieniczek

Medical University of Lublin
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
Lukasz KomstaLukasz Komsta
Lukasz Komsta
Robert SkibińskiRobert Skibiński
Robert Skibiński
ABAnna Berecka-Rycerz
Anna Berecka-Rycerz
Anna GumieniczekAnna Gumieniczek
Anna Gumieniczek
BRBeata Radkiewicz
Beata Radkiewicz
MRMałgorzata Radoń
Małgorzata Radoń

19 August 2021 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
ABAnna Biernasiuk
Anna Biernasiuk
ABAnna Berecka-Rycerz
Anna Berecka-Rycerz
Anna GumieniczekAnna Gumieniczek
Anna Gumieniczek
MMMaria Malm
Maria Malm
KŁKrzysztof Z. Łączkowski
Krzysztof Z. Łączkowski
Anna MalmAnna Malm
Anna Malm
Recently, the occurrence of candidiasis has increased dramatically, especially in immunocompromised patients. Additionally, their treatment is often ineffective due to the resistance of yeasts to antimycotics. Therefore, there is a need to search for new antifungals. A series of nine newly synthesized thiazole derivatives containing the cyclopropane system, showing promising activity against Candida spp., has been further investigated. We decided to verify their antifungal activity towards clinical Candida albicans isolated from the oral cavity of patients with hematological malignancies and investigate the mode of action on fungal cell, the effect of combination with the selected antimycotics, toxicity to erythrocytes, and lipophilicity. These studies were performed by the broth microdilution method, test with sorbitol and ergosterol, checkerboard technique, erythrocyte lysis assay, and reversed phase thin-layer chromatography, respectively. All derivatives showed very strong activity (similar and even higher than nystatin) against all C. albicans isolates with minimal inhibitory concentration (MIC) = 0.008–7.81 µg/mL Their mechanism of action may be related to action within the fungal cell wall structure and/or within the cell membrane. The interactions between the derivatives and the selected antimycotics (nystatin, chlorhexidine, and thymol) showed additive effect only in the case of combination some of them and thymol. The erythrocyte lysis assay confirmed the low cytotoxicity of these compounds as compared to nystatin. The high lipophilicity of the derivatives was related with their high antifungal activity. The present studies confirm that the studied thiazole derivatives containing the cyclopropane system appear to be a very promising group of compounds in treatment of infections caused by C. albicans. However, this requires further studies in vivo. Key points: • The newly thiazoles showed high antifungal activity and some of them — additive effect in combination with thymol. • Their mode of action may be related with the influence on the structure of the fungal cell wall and/or the cell membrane. • The low cytotoxicity against erythrocytes and high lipophilicity of these derivatives are their additional good properties. Graphical


9 September 2019 in Medicinal Chemistry Research
Verified
Journal Article
Open access
PDF file
ABAnna Biernasiuk
Anna Biernasiuk
MKMagdalena Kawczyńska
Magdalena Kawczyńska
ABAnna Berecka-Rycerz
Anna Berecka-Rycerz
BRBeata Rosada
Beata Rosada
Anna GumieniczekAnna Gumieniczek
Anna Gumieniczek
KŁKrzysztof Z. Łączkowski
Krzysztof Z. Łączkowski
Synthesis and investigation of antimicrobial activity of fifteen novel thiazoles containing cyclohexene moiety are presented. Among the derivatives, compounds 3a–3d, 3f, 3n, and 3o showed very strong activity against the reference Candida spp. strains with MIC = 0.015–3.91 µg/ml. The activity of these compounds is similar and even higher than the activity of nystatin used as positive control. Compounds 3d, 3f, 3n, 3o showed the highest activity with very strong effect towards most of yeasts isolated from clinical materials with MIC = 0.015–7.81 µg/ml. The cytotoxicity studies for the most active compounds showed that Candida spp. growth was inhibited at noncytotoxic concentrations for the mammalian L929 fibroblast. In addition, a good correlation was obtained between lipophilicity of compounds determined using reversed phase thin-layer chromatography and their antifungal activity.

1 May 2005 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
Anna GumieniczekAnna Gumieniczek
Anna Gumieniczek

17 February 2020 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
KLKatarzyna Lipska
Katarzyna Lipska
Anna GumieniczekAnna Gumieniczek
Anna Gumieniczek
AFAgata A. Filip
Agata A. Filip
Results from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (HDAC) inhibitors (HDIs), being involved in the epigenetic regulation of gene expression. Afterward, VPA is shown to induce apoptosis and cell differentiation, as well as regulate Notch signaling. Moreover, it up-regulates the expression of certain G protein-coupled receptors (GPCRs), which are involved in various signaling pathways associated with cancer. As a consequence, some pre-clinical and clinical trials were carried out to estimate anticancer effectiveness of VPA, in monotherapy and in new drug combinations, while other SCFAs were tested in pre-clinical studies. The present manuscript summarizes the most important information from the literature about their potent anticancer activities to show some future perspectives related to epigenetic therapy.